title: Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms.
abstract: We recently reported that Inosine Monophosphate Dehydrogenase (IMPDH), a rate-limiting enzyme in de novo guanine nucleotide biosynthesis, clustered into macrostructures in response to decreased nucleotide levels and that there were differences between the IMPDH isoforms, IMPDH1 and IMPDH2. We hypothesised that the Bateman domains, which are present in both isoforms and serve as energy-sensing/allosteric modules in unrelated proteins, would contribute to isoform-specific differences and that mutations situated in and around this domain in IMPDH1 which give rise to retinitis pigmentosa (RP) would compromise regulation. We employed immuno-electron microscopy to investigate the ultrastructure of IMPDH macrostructures and live-cell imaging to follow clustering of an IMPDH2-GFP chimera in real-time. Using a series of IMPDH1/IMPDH2 chimera we demonstrated that the propensity to cluster was conferred by the N-terminal 244 amino acids, which includes the Bateman domain. A protease protection assay suggested isoform-specific purine nucleotide binding characteristics, with ATP protecting IMPDH1 and AMP protecting IMPDH2, via a mechanism involving conformational changes upon nucleotide binding to the Bateman domain without affecting IMPDH catalytic activity. ATP binding to IMPDH1 was confirmed in a nucleotide binding assay. The RP-causing mutation, R224P, abolished ATP binding and nucleotide protection and this correlated with an altered propensity to cluster. Collectively these data demonstrate that (i) the isoforms are differentially regulated by AMP and ATP by a mechanism involving the Bateman domain, (ii) communication occurs between the Bateman and catalytic domains and (iii) the RP-causing mutations compromise such regulation. These findings support the idea that the IMPDH isoforms are subject to distinct regulation and that regulatory defects contribute to human disease.
authors.affiliation: Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia. elaine.thomas@bristol.ac.uk
authors.forename: Elaine C
authors.initials: EC
authors.lastname: Thomas
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Gunter
authors.forename: Julie A
authors.initials: JA
authors.lastname: Webster
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Schieber
authors.forename: Viola
authors.initials: V
authors.lastname: Oorschot
authors.forename: Robert G
authors.initials: RG
authors.lastname: Parton
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Whitehead
mesh_terms: D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D006367:HeLa Cells; D006801:Humans; D007168:IMP Dehydrogenase / Q000235:genetics / Q000378:metabolism*; D009154:Mutation; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism*; D011685:Purine Nucleotides / Q000235:genetics / Q000378:metabolism*
chemical_list: D020033:Protein Isoforms; D011685:Purine Nucleotides; D007168:IMP Dehydrogenase